In our study, we set out to analyze the phenotype (with a particular focus on the inhibitory molecules CD244, PD-1, CD160, and TIM-3) and function (proliferation, cytokine production) of peripheral blood (PB) and bone marrow (BM) T cells in AML patients at different stages of the disease (diagnosis, relapse after intensive chemotherapy, relapse after allogeneic stem cell transplantation (allo-SCT)) in comparison to healthy controls (HC) and untreated HIV-infected patients. This evidence concerns the gene CD244 and acute myeloid leukemia.